New Opioid DFNZ Offers Pain Relief Without Addiction or Breathing Risks

Scientists have discovered a powerful new opioid that relieves pain without the usual risks of addiction or breathing problems. The compound, called DFNZ, was developed from an old synthetic drug and shows unusual safety in early tests. Researchers believe it could one day offer a better alternative to current treatments for opioid use disorder. DFNZ comes from a class of drugs known as nitazenes, originally explored in the 1950s. It was created as a metabolite of FNZ, a compound abandoned decades ago. Unlike traditional opioids, DFNZ targets the mu-opioid receptor with extreme strength but without dangerous side effects.

Tests in rats revealed striking differences from other opioids. Animals stopped seeking DFNZ as soon as it was replaced with saline, suggesting very low addiction potential. The drug also failed to suppress breathing—instead, it slightly increased oxygen levels in the brain. The researchers found that DFNZ triggers a slow, steady release of dopamine rather than the rapid spikes linked to addiction. This provides pain relief and a sense of reward without the usual risks. The study, funded by the NIH Intramural Research Program and an NIH/NIDA grant, challenges the idea that stronger opioids must be more dangerous. No human trials are planned yet. The team will first conduct more preclinical studies to gather data for future regulatory approval.

DFNZ's unique properties make it a promising candidate for safer pain treatment and opioid use disorder therapy. If further animal studies succeed, the drug could move toward human testing. For now, researchers continue exploring its potential under controlled lab conditions.